Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Checklist for Prescribers - Bimizza 150 microgram/20 microgram Tablets

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. •Thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, heart attack and stroke) is a rare but important risk with use of a CHC.

For Healthcare Professionals

Important Information for Women Leaflet - Bimizza 150 microgram/20 microgram Tablets

All women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

Patient Alert Card - Bimizza 150 microgram/20 microgram Tablets

IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.